OPTIMISE-CKD Study_current Clinical Landscape in Spain
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
91,628actual
Sites
1
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-04 | actual | When the study began enrolling |
| Primary completion | 2025-10-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-06 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Renal Disease
Interventions
- Other: Pre-pricing & reimbursement, incident renal disease cohort (study observation period 2020- 2024)
- Other: Post-pricing & reimbursement, incident renal disease cohort (study observation period 2023-2024)
Primary outcomes
what the primary-completion date above is the date OFBaseline demographics and clinical characteristics of the two cohorts of the study, pre-P&R and post-P&R cohorts, at their respective index dates.
measured from the 1st August 2020 to 30th September 2024
Baseline laboratory measures (number of measures per year and their values) of the two cohorts of the study, pre-P&R and post-P&R cohorts, at their respective index dates.
measured from the 1st August 2020 to 30th September 2024
Concomitant medications, by drug class and specific drugs of interest (proportion of patients with prescription of selected drugs) of the two cohorts of the study, pre-P&R and post-P&R cohorts, at their respective index dates.
measured Concomitant medications, by drug class and specific drugs of interest (proportion of patients with prescription of selected drugs) of the two cohorts of the study, pre-P&R and post-P&R cohorts, at their respective index dates.
Initiation of kidney-protective treatment (RAASi or SGLT2i or both) among treatment naïve patients in the pre-P&R cohort and post- P&R
measured from the 1st August 2020 to 30th September 2024
Discontinuation of newly initiated RAASi or SGLT-2i treatment in the two cohorts of the study, pre-P&R and post-P&R cohorts
measured from the 1st August 2020 to 30th September 2024
Discontinuation of ongoing RAASi and/or SGLT-2i treatment among treated patients (proportion of patients, time to discontinuation) in the two cohorts of the study, pre-P&R and post-P&R cohorts.
measured from the 1st August 2020 to 30th September 2024
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed